Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994779 | 1.00 | KMT2A (0.46) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL13275252 | 0.86 | MEN1 (0.45) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL13275253 | 0.86 | MEN1 (0.45) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL22821132 | 0.85 | MEN1 (0.42) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL28567559 | 0.85 | MEN1 (0.42) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL19734564 | 0.84 | KMT2A (0.45) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL3709552 | 0.83 | MEN1 (0.47) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL28689687 | 0.80 | MEN1 (0.40) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL28683423 | 0.80 | MEN1 (0.40) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL22821135 | 0.80 | ALDH1A1 (0.46) | KMT2AMEN1NPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | KMT2A 3206/4885MEN1 2257/4885NPC1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.